CAR-T in Autoimmune Disorders

Beyond oncology, GenCART is exploring the groundbreaking potential of CAR-T therapy for autoimmune diseases. By reprogramming a patient’s immune cells to selectively eliminate the aberrant B cells that drive autoimmunity, this approach could provide lasting remission without chronic immunosuppression.

GenCART’s investigational CAR-T programs are being evaluated for several autoimmune conditions, including:

• Systemic Lupus Erythematosus (SLE)
• Multiple Sclerosis (MS)
• Rheumatoid Arthritis (RA)
• Myasthenia Gravis (MG)
• Autoimmune Hemolytic Anemia (AIHA)
• Neuromyelitis Optica Spectrum Disorder (NMOSD)

Our goal is to redefine treatment paradigms for these chronic and often debilitating conditions by restoring immune tolerance at its cellular root.